Charles River Laboratories (CRL) Q3 2025 earnings summary

Executive summary

• Strategic review completed, focusing on strengthening the scientific portfolio, divesting underperforming/non-core assets (~7% of 2025 revenue), and disciplined capital deployment to maximize long-term shareholder value.

• Board approved a new $1 billion stock repurchase authorization, replacing the prior program; $450.7 million repurchased since August 2024.

• Demand trends stabilized in Q3 2025, with improved biotech funding, positive DSA proposal activity, and client restructuring largely complete.

• Portfolio investments target growth in bioanalysis, in vitro services, and NAMs, with operational streamlining and efficiency initiatives.

• Management remains cautious due to sector uncertainty, ongoing legal/regulatory risks, and macroeconomic headwinds.

Financial highlights

• Q3 2025 revenue was $1,004.9 million, down 0.5% year-over-year; organic revenue declined 1.6%.

• GAAP operating margin rose to 13.3% (up from 11.6%); non-GAAP operating margin was 19.7% (down 20 bps year-over-year).

• GAAP EPS was $1.10 (down from $1.33); non-GAAP EPS was $2.43 (down 6.2% year-over-year), modestly above prior outlook.

• Free cash flow for Q3 was $178.2 million, down from $213.1 million last year, but improved sequentially; FY 2025 FCF guidance raised to $470–$500 million.

• Cash flow from operations for the nine months ended September 27, 2025, was $590.1 million.

Outlook and guidance

• 2025 organic revenue expected to decline 1.5%–2.5%; reported revenue down 1.5%–0.5%.

• Non-GAAP EPS guidance raised to $10.10–$10.30; GAAP EPS guidance is $4.15–$4.35.

• DSA organic revenue outlook narrowed to a 2.5%–3.5% decline; Manufacturing segment expected flat to slightly negative.

• Free cash flow guidance increased to $470–$500 million for 2025; CapEx expected at $200 million.

• Restructuring actions expected to yield $225 million in annualized cost savings, with $70 million incremental savings fully realized in 2026.